← Eichor
Study identifier: NCT06189820 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases

Condition: Pulmonary Fibrosis · Lung Fibrosis · Idiopathic Pulmonary Fibrosis  ·  Sponsor: Erasme University Hospital

PhasePhase 2
Planned participants70
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.

This description comes directly from the study's public registry record.

Talk to the study team

Benjamin Bondue  ·  + 32 (2) 555 5758  ·  benjamin.bondue@hubruxelles.be

Always discuss trial participation with your own doctor first.

Locations (1)

MedecineBrussels, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06189820